Drug Profile
Meclinertant
Alternative Names: Reminertant; SR 48692Latest Information Update: 28 Feb 2006
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Analgesics; Antineoplastics; Antipsychotics
- Mechanism of Action Neurotensin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anorexia nervosa; Cancer; Colorectal cancer; Irritable bowel syndrome; Pain; Pancreatic cancer; Prostate cancer; Schizophrenia; Small cell lung cancer
Most Recent Events
- 24 Feb 2006 Discontinued - Phase-II for Small cell lung cancer in France (unspecified route)
- 10 Mar 2005 Discontinued - Phase-II for Anorexia nervosa in France (unspecified route)
- 10 Mar 2005 Discontinued - Phase-II for Colorectal cancer in France (unspecified route)